Zhiwei Gao

Dr. Zhiwei Gao

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JAJoseph Emil Amegadzie
Joseph Emil Amegadzie
JGJM Gamble
JM Gamble
JFJamie Farrell
Jamie Farrell
ZGZhiwei Gao
Zhiwei Gao
Purpose: Despite ample evidence underpinning the efficacy of β2-agonists in asthma and chronic obstructive pulmonary disease (COPD), the occurrence of β1- and β2-adrenoceptors in the heart suggests that β2-agonists may have deleterious cardiac effects. We investigated the association between new users of long-or short-acting β2-agonists (LABA or SABA) or ICS (inhaled corticosteroids)/LABA and major adverse cardiovascular events (MACE). Methods: A nested case–control analysis was conducted using the UK Clinical Practice Research Datalink of patients with asthma, COPD or asthma–COPD overlap with initial treatment of LABA, SABA, ICS/LABA, ICS, long-or short-acting muscarinic antagonist (LAMA or SAMA) between 01 January 1998 and 31 July 2018. The primary outcome was MACE, defined as the first occurrence of stroke, heart failure, myocardial infarction, arrhythmia, or cardiovascular death. Each case was matched with up to 10 controls on age, sex, date of cohort-entry, and duration of follow-up. The risk of MACE associated with β2-agonists was estimated using conditional logistic regression after controlling for potential confounders. Results: The cohort included 180,567 new users of β2-agonists, ICS, SAMA, or LAMA. Among asthmatics, β2-agonists were not associated with the risk of MACE (SABA vs ICS: HR 1.29 [0.96– 1.73]; ICS/LABA vs ICS, HR 0.75 [0.33– 1.73]). In contrast, among COPD patients, LABA (HR, 2.38 [1.04– 5.47]), SABA (HR, 2.02 [1.13– 3.59]) and ICS/LABA (HR, 2.08 [1.04– 4.16]) users had an increased risk of MACE compared with SAMA users. Among patients with asthma–COPD overlap, SABA (HR, 2.57 [1.26– 5.24]) was associated with an increased risk of MACE compared with ICS. Conclusion: In conclusion, initiation of LABA, SABA, or ICS/LABA in COPD or SABA in asthma–COPD overlap is associated with increased risk of MACE. No associations were observed among patients with asthma.

2 December 2018 in International Journal of Chronic Diseases
Verified
Journal Article
Open access
PDF file
NLNelson Lau
Nelson Lau
ANAlex Norman
Alex Norman
MSMary Jane Smith
Mary Jane Smith
ASAtanu Sarkar
Atanu Sarkar
ZGZhiwei Gao
Zhiwei Gao
Introduction. Traffic related air pollution (TRAP) has long been associated with the onset of childhood asthma. The relationship between TRAP exposure and the development of childhood asthma phenotypes is less understood. To better understand this relationship, we performed a systematic review of the literature studying childhood TRAP exposure and the development of childhood asthma and wheezing phenotypes (transient, persistent, and late-onset asthma/wheezing phenotypes). Methods. A literature search was performed in PubMed, Embase, and Scopus databases for current literature, returning 1706 unique articles. After screening and selection, 7 articles were included in the final review. Due to the low number of articles, no meta-analysis was performed. Results. TRAP exposure appears to be associated with both transient and persistent asthma/wheezing phenotypes. However, there was little evidence to suggest a relationship between TRAP exposure and late-onset asthma/wheezing. The differing results may be in part due to the heterogeneity in study methods and asthma/wheezing phenotype definitions, in addition to other factors such as genetics. Conclusion. TRAP exposure may be associated with transient and persistent asthma/wheezing phenotypes in children. The low number of studies and differing results suggest that further studies are warranted.

14 January 2022 in JMIR Diabetes
Verified
Journal Article
Open access
RBRyan Batten
Ryan Batten
meshari alwashmimeshari alwashmi
meshari alwashmi
GMGerald Mugford
Gerald Mugford
MNMisa Nuccio
Misa Nuccio
ABAngele Besner
Angele Besner
ZGZhiwei Gao
Zhiwei Gao
Background: The prevalence of diabetes is increasing rapidly. Previous research has demonstrated the efficacy of a diabetes prevention program (DPP) in lifestyle modifications that can prevent or delay the onset of type 2 diabetes among individuals at risk. Digital DPPs have the potential to use technology, in conjunction with behavior change science, to prevent prediabetes on a national and global scale. Objective: The aim of this study is to investigate the effects of a digital DPP (Virgin Pulse [VP] Transform for Prediabetes) on weight and physical activity among participants who had completed 12 months of the program. Methods: This study was a secondary analysis of retrospective data of adults with prediabetes who were enrolled in VP Transform for Prediabetes for 12 months of the program. The program incorporates interactive mobile computing, remote monitoring, an evidence-based curriculum, behavior tracking tools, health coaching, and online peer support to prevent or delay the onset of type 2 diabetes. Results: The sample (N=1095) was comprised of people with prediabetes who completed at least 9 months of the VP Transform for Prediabetes program. Participants were 67.7% (n=741) female, with a mean age of 53.6 (SD 9.75) years. After 12 months, participants decreased their weight by an average of 10.9 lbs (5.5%; P<.001) and increased their physical activity by 91.2 (P<.001) minutes. Conclusions: These results suggest that VP Transform for Prediabetes is effective at preventing type 2 diabetes through a significant reduction in body weight and increase of physical activity. Furthermore, these results suggest that the DPP remains effective 12 months after beginning the program. A prospective randomized controlled clinical study is warranted to validate these findings.

29 March 2020 in American Journal of Industrial Medicine
Verified
Journal Article
Closed access
PDF file
AKAnya R. Keefe
Anya R. Keefe
PDPaul A Demers
Paul A Demers
BNBarbara Neis
Barbara Neis
VAVictoria Arrandale
Victoria Arrandale
HDHugh W. Davies
Hugh W. Davies
SBStephen Bornstein
Stephen Bornstein

3 September 2021 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
UOUgochukwu Odimba
Ugochukwu Odimba
ASAmbikaipakn Senthilselvan
Ambikaipakn Senthilselvan
JFJamie Farrell
Jamie Farrell
ZGZhiwei Gao
Zhiwei Gao
Asthma-COPD overlap (ACO) is a newly identified phenotype of chronic obstructive airway diseases with shared asthma and COPD features. Patients with ACO are poorly defined, and some evidence suggests that they have worse health outcomes and greater disease burden than patients with COPD or asthma. Generally, there is no evidence-based and universal definition for ACO; several consensus documents have provided various descriptions of the phenotype. In addition, the mechanisms underlying the development of ACO are not fully understood. Whether ACO is a distinct clinical entity with its particular discrete genetic determinant different from asthma and COPD alone or an intermediate phenotype with overlapping genetic markers within asthma and COPD spectrum of obstructive airway disease remains unproven. This review summarizes the current knowledge of the genetic risk factors, characteristics, and prognosis of ACO.

1 December 2020 in Environmental Research
Verified
Journal Article
Closed access
NLNelson Lau
Nelson Lau
MSMary Jane Smith
Mary Jane Smith
ASAtanu Sarkar
Atanu Sarkar
ZGZhiwei Gao
Zhiwei Gao